What are the barriers that could stop HIV treatment becoming HIV prevention?
Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?
Of guidelines, targets and resources: the documents that defined the 2014 International AIDS Conference
Protease inhibitor therapy increases underlying genetic risk of diabetes for women with HIV
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs
